nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO2B1—Niacin—atherosclerosis	0.217	0.305	CbGbCtD
Alprostadil—SLCO2B1—Rosuvastatin—atherosclerosis	0.184	0.26	CbGbCtD
Alprostadil—SLCO2B1—Pravastatin—atherosclerosis	0.167	0.236	CbGbCtD
Alprostadil—ABCC4—Rosuvastatin—atherosclerosis	0.141	0.198	CbGbCtD
Alprostadil—Neoplasm skin—Niacin—atherosclerosis	0.00875	0.063	CcSEcCtD
Alprostadil—Pain localised—Pravastatin—atherosclerosis	0.00862	0.062	CcSEcCtD
Alprostadil—Ethanolamine Oleate—FABP4—atherosclerosis	0.00547	0.92	CrCbGaD
Alprostadil—Regurgitation—Lovastatin—atherosclerosis	0.00481	0.0346	CcSEcCtD
Alprostadil—Regurgitation—Simvastatin—atherosclerosis	0.0045	0.0324	CcSEcCtD
Alprostadil—Nodule—Lovastatin—atherosclerosis	0.004	0.0287	CcSEcCtD
Alprostadil—Nodule—Simvastatin—atherosclerosis	0.00374	0.0269	CcSEcCtD
Alprostadil—PTGIR—artery—atherosclerosis	0.00365	0.157	CbGeAlD
Alprostadil—Fibrosis—Niacin—atherosclerosis	0.00353	0.0254	CcSEcCtD
Alprostadil—Nodule—Pravastatin—atherosclerosis	0.00338	0.0243	CcSEcCtD
Alprostadil—Warmth—Niacin—atherosclerosis	0.00317	0.0228	CcSEcCtD
Alprostadil—PTGIR—endothelium—atherosclerosis	0.00308	0.133	CbGeAlD
Alprostadil—PTGIR—blood vessel—atherosclerosis	0.00284	0.122	CbGeAlD
Alprostadil—Leg pain—Lovastatin—atherosclerosis	0.00254	0.0183	CcSEcCtD
Alprostadil—Prostatic disorder—Niacin—atherosclerosis	0.00237	0.0171	CcSEcCtD
Alprostadil—Trauma—Pravastatin—atherosclerosis	0.00209	0.015	CcSEcCtD
Alprostadil—PTGER2—adipose tissue—atherosclerosis	0.00191	0.0822	CbGeAlD
Alprostadil—Accidental injury—Rosuvastatin—atherosclerosis	0.00157	0.0113	CcSEcCtD
Alprostadil—Redness—Niacin—atherosclerosis	0.00149	0.0107	CcSEcCtD
Alprostadil—PTGIR—connective tissue—atherosclerosis	0.00146	0.0628	CbGeAlD
Alprostadil—Burning sensation—Niacin—atherosclerosis	0.00145	0.0104	CcSEcCtD
Alprostadil—Accidental injury—Lovastatin—atherosclerosis	0.00133	0.00955	CcSEcCtD
Alprostadil—Feeling hot—Niacin—atherosclerosis	0.00129	0.00924	CcSEcCtD
Alprostadil—PTGIR—cardiovascular system—atherosclerosis	0.00127	0.0546	CbGeAlD
Alprostadil—Numbness—Pravastatin—atherosclerosis	0.0012	0.00862	CcSEcCtD
Alprostadil—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.00116	0.00832	CcSEcCtD
Alprostadil—Sensory loss—Pravastatin—atherosclerosis	0.00115	0.00825	CcSEcCtD
Alprostadil—PTGIR—adipose tissue—atherosclerosis	0.00112	0.0482	CbGeAlD
Alprostadil—Hyperbilirubinaemia—Niacin—atherosclerosis	0.00111	0.00798	CcSEcCtD
Alprostadil—Injury—Rosuvastatin—atherosclerosis	0.00109	0.00787	CcSEcCtD
Alprostadil—SLCO3A1—adipose tissue—atherosclerosis	0.000986	0.0425	CbGeAlD
Alprostadil—SLCO2A1—adipose tissue—atherosclerosis	0.000976	0.0421	CbGeAlD
Alprostadil—Injury—Lovastatin—atherosclerosis	0.000928	0.00667	CcSEcCtD
Alprostadil—Cramps of lower extremities—Niacin—atherosclerosis	0.000927	0.00667	CcSEcCtD
Alprostadil—Diabetes mellitus—Simvastatin—atherosclerosis	0.000917	0.0066	CcSEcCtD
Alprostadil—Swelling—Simvastatin—atherosclerosis	0.000904	0.0065	CcSEcCtD
Alprostadil—ABCC5—adipose tissue—atherosclerosis	0.000893	0.0385	CbGeAlD
Alprostadil—Abnormal vision—Niacin—atherosclerosis	0.00088	0.00633	CcSEcCtD
Alprostadil—Influenza—Rosuvastatin—atherosclerosis	0.00087	0.00625	CcSEcCtD
Alprostadil—Pain in extremity—Lovastatin—atherosclerosis	0.000853	0.00613	CcSEcCtD
Alprostadil—Diabetes mellitus—Niacin—atherosclerosis	0.000842	0.00606	CcSEcCtD
Alprostadil—Pain in extremity—Ezetimibe—atherosclerosis	0.000836	0.00602	CcSEcCtD
Alprostadil—Bronchitis—Rosuvastatin—atherosclerosis	0.000836	0.00602	CcSEcCtD
Alprostadil—Injury—Pravastatin—atherosclerosis	0.000784	0.00564	CcSEcCtD
Alprostadil—PTGIR—liver—atherosclerosis	0.000783	0.0338	CbGeAlD
Alprostadil—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000754	0.00542	CcSEcCtD
Alprostadil—Haematuria—Rosuvastatin—atherosclerosis	0.000739	0.00532	CcSEcCtD
Alprostadil—Influenza—Lovastatin—atherosclerosis	0.000737	0.0053	CcSEcCtD
Alprostadil—Sinusitis—Rosuvastatin—atherosclerosis	0.000727	0.00523	CcSEcCtD
Alprostadil—Influenza—Ezetimibe—atherosclerosis	0.000723	0.0052	CcSEcCtD
Alprostadil—SLCO2B1—adipose tissue—atherosclerosis	0.000699	0.0301	CbGeAlD
Alprostadil—Rhinitis—Rosuvastatin—atherosclerosis	0.000698	0.00502	CcSEcCtD
Alprostadil—SLCO3A1—liver—atherosclerosis	0.000691	0.0298	CbGeAlD
Alprostadil—Pharyngitis—Rosuvastatin—atherosclerosis	0.000691	0.00497	CcSEcCtD
Alprostadil—SLCO2A1—liver—atherosclerosis	0.000685	0.0295	CbGeAlD
Alprostadil—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000672	0.00483	CcSEcCtD
Alprostadil—Bronchitis—Simvastatin—atherosclerosis	0.000663	0.00477	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000641	0.00461	CcSEcCtD
Alprostadil—Urinary tract infection—Lovastatin—atherosclerosis	0.000639	0.00459	CcSEcCtD
Alprostadil—Influenza—Niacin—atherosclerosis	0.000633	0.00455	CcSEcCtD
Alprostadil—ABCC5—liver—atherosclerosis	0.000626	0.027	CbGeAlD
Alprostadil—Influenza—Pravastatin—atherosclerosis	0.000623	0.00448	CcSEcCtD
Alprostadil—ABCC4—adipose tissue—atherosclerosis	0.000619	0.0267	CbGeAlD
Alprostadil—Sinusitis—Lovastatin—atherosclerosis	0.000616	0.00443	CcSEcCtD
Alprostadil—Bronchitis—Niacin—atherosclerosis	0.000609	0.00438	CcSEcCtD
Alprostadil—Sweating increased—Pravastatin—atherosclerosis	0.000607	0.00437	CcSEcCtD
Alprostadil—Sinusitis—Ezetimibe—atherosclerosis	0.000605	0.00435	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000579	0.00417	CcSEcCtD
Alprostadil—Sinusitis—Simvastatin—atherosclerosis	0.000577	0.00415	CcSEcCtD
Alprostadil—Pharyngitis—Ezetimibe—atherosclerosis	0.000574	0.00413	CcSEcCtD
Alprostadil—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000548	0.00394	CcSEcCtD
Alprostadil—Flushing—Lovastatin—atherosclerosis	0.000547	0.00394	CcSEcCtD
Alprostadil—Myocardial infarction—Pravastatin—atherosclerosis	0.000545	0.00392	CcSEcCtD
Alprostadil—Urinary tract infection—Pravastatin—atherosclerosis	0.00054	0.00388	CcSEcCtD
Alprostadil—Flushing—Ezetimibe—atherosclerosis	0.000537	0.00386	CcSEcCtD
Alprostadil—Cough—Rosuvastatin—atherosclerosis	0.000529	0.0038	CcSEcCtD
Alprostadil—Sinusitis—Pravastatin—atherosclerosis	0.000521	0.00375	CcSEcCtD
Alprostadil—Flushing—Simvastatin—atherosclerosis	0.000512	0.00368	CcSEcCtD
Alprostadil—Haemoglobin—Niacin—atherosclerosis	0.000509	0.00366	CcSEcCtD
Alprostadil—Rhinitis—Niacin—atherosclerosis	0.000508	0.00365	CcSEcCtD
Alprostadil—Haemorrhage—Niacin—atherosclerosis	0.000507	0.00364	CcSEcCtD
Alprostadil—Hypoaesthesia—Niacin—atherosclerosis	0.000504	0.00363	CcSEcCtD
Alprostadil—Erythema—Ezetimibe—atherosclerosis	0.000504	0.00362	CcSEcCtD
Alprostadil—Rhinitis—Pravastatin—atherosclerosis	0.0005	0.0036	CcSEcCtD
Alprostadil—Back pain—Lovastatin—atherosclerosis	0.000497	0.00357	CcSEcCtD
Alprostadil—Hypoaesthesia—Pravastatin—atherosclerosis	0.000496	0.00357	CcSEcCtD
Alprostadil—Pharyngitis—Pravastatin—atherosclerosis	0.000495	0.00356	CcSEcCtD
Alprostadil—Muscle spasms—Lovastatin—atherosclerosis	0.000494	0.00355	CcSEcCtD
Alprostadil—Infection—Rosuvastatin—atherosclerosis	0.000491	0.00353	CcSEcCtD
Alprostadil—SLCO2B1—liver—atherosclerosis	0.00049	0.0211	CbGeAlD
Alprostadil—Visual impairment—Niacin—atherosclerosis	0.000488	0.00351	CcSEcCtD
Alprostadil—Back pain—Ezetimibe—atherosclerosis	0.000487	0.0035	CcSEcCtD
Alprostadil—Muscle spasms—Ezetimibe—atherosclerosis	0.000484	0.00348	CcSEcCtD
Alprostadil—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000484	0.00348	CcSEcCtD
Alprostadil—Visual impairment—Pravastatin—atherosclerosis	0.000481	0.00346	CcSEcCtD
Alprostadil—Erythema—Simvastatin—atherosclerosis	0.00048	0.00345	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—atherosclerosis	0.000474	0.0797	CrCbGaD
Alprostadil—Flushing—Niacin—atherosclerosis	0.00047	0.00338	CcSEcCtD
Alprostadil—Anaemia—Ezetimibe—atherosclerosis	0.000465	0.00335	CcSEcCtD
Alprostadil—Flushing—Pravastatin—atherosclerosis	0.000463	0.00333	CcSEcCtD
Alprostadil—Muscle spasms—Simvastatin—atherosclerosis	0.000462	0.00332	CcSEcCtD
Alprostadil—Anaemia—Simvastatin—atherosclerosis	0.000444	0.00319	CcSEcCtD
Alprostadil—Erythema—Niacin—atherosclerosis	0.000441	0.00317	CcSEcCtD
Alprostadil—Cough—Ezetimibe—atherosclerosis	0.000439	0.00316	CcSEcCtD
Alprostadil—Dyspepsia—Rosuvastatin—atherosclerosis	0.000435	0.00313	CcSEcCtD
Alprostadil—Hypertension—Ezetimibe—atherosclerosis	0.000435	0.00313	CcSEcCtD
Alprostadil—ABCC4—liver—atherosclerosis	0.000434	0.0187	CbGeAlD
Alprostadil—Discomfort—Lovastatin—atherosclerosis	0.000432	0.00311	CcSEcCtD
Alprostadil—Nervousness—Niacin—atherosclerosis	0.000428	0.00308	CcSEcCtD
Alprostadil—Dry mouth—Lovastatin—atherosclerosis	0.000428	0.00308	CcSEcCtD
Alprostadil—Muscle spasms—Niacin—atherosclerosis	0.000424	0.00305	CcSEcCtD
Alprostadil—Discomfort—Ezetimibe—atherosclerosis	0.000424	0.00305	CcSEcCtD
Alprostadil—Pain—Rosuvastatin—atherosclerosis	0.000423	0.00304	CcSEcCtD
Alprostadil—Nervousness—Pravastatin—atherosclerosis	0.000422	0.00303	CcSEcCtD
Alprostadil—Dry mouth—Ezetimibe—atherosclerosis	0.000419	0.00302	CcSEcCtD
Alprostadil—Muscle spasms—Pravastatin—atherosclerosis	0.000417	0.003	CcSEcCtD
Alprostadil—Infection—Lovastatin—atherosclerosis	0.000416	0.00299	CcSEcCtD
Alprostadil—Thrombocytopenia—Lovastatin—atherosclerosis	0.00041	0.00295	CcSEcCtD
Alprostadil—Infection—Ezetimibe—atherosclerosis	0.000408	0.00294	CcSEcCtD
Alprostadil—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000407	0.00293	CcSEcCtD
Alprostadil—Discomfort—Simvastatin—atherosclerosis	0.000404	0.00291	CcSEcCtD
Alprostadil—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000402	0.00289	CcSEcCtD
Alprostadil—Anaemia—Pravastatin—atherosclerosis	0.000401	0.00289	CcSEcCtD
Alprostadil—Skin disorder—Ezetimibe—atherosclerosis	0.000399	0.00287	CcSEcCtD
Alprostadil—Syncope—Niacin—atherosclerosis	0.000395	0.00284	CcSEcCtD
Alprostadil—Oedema—Simvastatin—atherosclerosis	0.000392	0.00282	CcSEcCtD
Alprostadil—Abdominal pain—Rosuvastatin—atherosclerosis	0.000391	0.00281	CcSEcCtD
Alprostadil—Infection—Simvastatin—atherosclerosis	0.000389	0.0028	CcSEcCtD
Alprostadil—Loss of consciousness—Niacin—atherosclerosis	0.000388	0.00279	CcSEcCtD
Alprostadil—Cough—Niacin—atherosclerosis	0.000385	0.00277	CcSEcCtD
Alprostadil—Thrombocytopenia—Simvastatin—atherosclerosis	0.000384	0.00276	CcSEcCtD
Alprostadil—Cough—Pravastatin—atherosclerosis	0.000379	0.00273	CcSEcCtD
Alprostadil—Hypertension—Pravastatin—atherosclerosis	0.000375	0.0027	CcSEcCtD
Alprostadil—Dyspepsia—Lovastatin—atherosclerosis	0.000369	0.00265	CcSEcCtD
Alprostadil—Dry mouth—Niacin—atherosclerosis	0.000367	0.00264	CcSEcCtD
Alprostadil—Discomfort—Pravastatin—atherosclerosis	0.000365	0.00263	CcSEcCtD
Alprostadil—Dyspepsia—Ezetimibe—atherosclerosis	0.000362	0.0026	CcSEcCtD
Alprostadil—Oedema—Niacin—atherosclerosis	0.00036	0.00259	CcSEcCtD
Alprostadil—Pain—Lovastatin—atherosclerosis	0.000358	0.00258	CcSEcCtD
Alprostadil—Asthenia—Rosuvastatin—atherosclerosis	0.000355	0.00255	CcSEcCtD
Alprostadil—Oedema—Pravastatin—atherosclerosis	0.000354	0.00255	CcSEcCtD
Alprostadil—Shock—Niacin—atherosclerosis	0.000354	0.00255	CcSEcCtD
Alprostadil—Infection—Pravastatin—atherosclerosis	0.000352	0.00253	CcSEcCtD
Alprostadil—Pain—Ezetimibe—atherosclerosis	0.000351	0.00253	CcSEcCtD
Alprostadil—Tachycardia—Niacin—atherosclerosis	0.000351	0.00253	CcSEcCtD
Alprostadil—Pruritus—Rosuvastatin—atherosclerosis	0.00035	0.00252	CcSEcCtD
Alprostadil—Skin disorder—Niacin—atherosclerosis	0.00035	0.00251	CcSEcCtD
Alprostadil—Hyperhidrosis—Niacin—atherosclerosis	0.000348	0.0025	CcSEcCtD
Alprostadil—Thrombocytopenia—Pravastatin—atherosclerosis	0.000347	0.0025	CcSEcCtD
Alprostadil—Feeling abnormal—Lovastatin—atherosclerosis	0.000345	0.00248	CcSEcCtD
Alprostadil—Dyspepsia—Simvastatin—atherosclerosis	0.000345	0.00248	CcSEcCtD
Alprostadil—Hyperhidrosis—Pravastatin—atherosclerosis	0.000343	0.00246	CcSEcCtD
Alprostadil—Feeling abnormal—Ezetimibe—atherosclerosis	0.000339	0.00244	CcSEcCtD
Alprostadil—Diarrhoea—Rosuvastatin—atherosclerosis	0.000338	0.00243	CcSEcCtD
Alprostadil—Hypotension—Niacin—atherosclerosis	0.000336	0.00242	CcSEcCtD
Alprostadil—Pain—Simvastatin—atherosclerosis	0.000335	0.00241	CcSEcCtD
Alprostadil—Body temperature increased—Lovastatin—atherosclerosis	0.000331	0.00238	CcSEcCtD
Alprostadil—Abdominal pain—Lovastatin—atherosclerosis	0.000331	0.00238	CcSEcCtD
Alprostadil—Dizziness—Rosuvastatin—atherosclerosis	0.000327	0.00235	CcSEcCtD
Alprostadil—Body temperature increased—Ezetimibe—atherosclerosis	0.000325	0.00234	CcSEcCtD
Alprostadil—Abdominal pain—Ezetimibe—atherosclerosis	0.000325	0.00234	CcSEcCtD
Alprostadil—Feeling abnormal—Simvastatin—atherosclerosis	0.000323	0.00232	CcSEcCtD
Alprostadil—Dyspepsia—Niacin—atherosclerosis	0.000317	0.00228	CcSEcCtD
Alprostadil—Dyspepsia—Pravastatin—atherosclerosis	0.000312	0.00224	CcSEcCtD
Alprostadil—Rash—Rosuvastatin—atherosclerosis	0.000312	0.00224	CcSEcCtD
Alprostadil—Dermatitis—Rosuvastatin—atherosclerosis	0.000311	0.00224	CcSEcCtD
Alprostadil—Body temperature increased—Simvastatin—atherosclerosis	0.00031	0.00223	CcSEcCtD
Alprostadil—Abdominal pain—Simvastatin—atherosclerosis	0.00031	0.00223	CcSEcCtD
Alprostadil—Headache—Rosuvastatin—atherosclerosis	0.00031	0.00223	CcSEcCtD
Alprostadil—Pain—Niacin—atherosclerosis	0.000308	0.00221	CcSEcCtD
Alprostadil—Pain—Pravastatin—atherosclerosis	0.000303	0.00218	CcSEcCtD
Alprostadil—Asthenia—Lovastatin—atherosclerosis	0.000301	0.00216	CcSEcCtD
Alprostadil—Pruritus—Lovastatin—atherosclerosis	0.000296	0.00213	CcSEcCtD
Alprostadil—Asthenia—Ezetimibe—atherosclerosis	0.000295	0.00212	CcSEcCtD
Alprostadil—Nausea—Rosuvastatin—atherosclerosis	0.000294	0.00211	CcSEcCtD
Alprostadil—Feeling abnormal—Pravastatin—atherosclerosis	0.000292	0.0021	CcSEcCtD
Alprostadil—Pruritus—Ezetimibe—atherosclerosis	0.000291	0.00209	CcSEcCtD
Alprostadil—Diarrhoea—Lovastatin—atherosclerosis	0.000287	0.00206	CcSEcCtD
Alprostadil—Abdominal pain—Niacin—atherosclerosis	0.000285	0.00205	CcSEcCtD
Alprostadil—Body temperature increased—Niacin—atherosclerosis	0.000285	0.00205	CcSEcCtD
Alprostadil—Asthenia—Simvastatin—atherosclerosis	0.000281	0.00202	CcSEcCtD
Alprostadil—Diarrhoea—Ezetimibe—atherosclerosis	0.000281	0.00202	CcSEcCtD
Alprostadil—Body temperature increased—Pravastatin—atherosclerosis	0.00028	0.00202	CcSEcCtD
Alprostadil—Abdominal pain—Pravastatin—atherosclerosis	0.00028	0.00202	CcSEcCtD
Alprostadil—Pruritus—Simvastatin—atherosclerosis	0.000277	0.00199	CcSEcCtD
Alprostadil—Dizziness—Lovastatin—atherosclerosis	0.000277	0.00199	CcSEcCtD
Alprostadil—Dizziness—Ezetimibe—atherosclerosis	0.000272	0.00196	CcSEcCtD
Alprostadil—Diarrhoea—Simvastatin—atherosclerosis	0.000268	0.00193	CcSEcCtD
Alprostadil—Rash—Lovastatin—atherosclerosis	0.000264	0.0019	CcSEcCtD
Alprostadil—Dermatitis—Lovastatin—atherosclerosis	0.000264	0.0019	CcSEcCtD
Alprostadil—Headache—Lovastatin—atherosclerosis	0.000263	0.00189	CcSEcCtD
Alprostadil—Dizziness—Simvastatin—atherosclerosis	0.000259	0.00186	CcSEcCtD
Alprostadil—Rash—Ezetimibe—atherosclerosis	0.000259	0.00186	CcSEcCtD
Alprostadil—Dermatitis—Ezetimibe—atherosclerosis	0.000259	0.00186	CcSEcCtD
Alprostadil—Asthenia—Niacin—atherosclerosis	0.000258	0.00186	CcSEcCtD
Alprostadil—Headache—Ezetimibe—atherosclerosis	0.000257	0.00185	CcSEcCtD
Alprostadil—Pruritus—Niacin—atherosclerosis	0.000255	0.00183	CcSEcCtD
Alprostadil—Asthenia—Pravastatin—atherosclerosis	0.000254	0.00183	CcSEcCtD
Alprostadil—Pruritus—Pravastatin—atherosclerosis	0.000251	0.0018	CcSEcCtD
Alprostadil—Nausea—Lovastatin—atherosclerosis	0.000249	0.00179	CcSEcCtD
Alprostadil—Rash—Simvastatin—atherosclerosis	0.000247	0.00178	CcSEcCtD
Alprostadil—Dermatitis—Simvastatin—atherosclerosis	0.000247	0.00178	CcSEcCtD
Alprostadil—Diarrhoea—Niacin—atherosclerosis	0.000246	0.00177	CcSEcCtD
Alprostadil—Headache—Simvastatin—atherosclerosis	0.000246	0.00177	CcSEcCtD
Alprostadil—Nausea—Ezetimibe—atherosclerosis	0.000244	0.00176	CcSEcCtD
Alprostadil—Diarrhoea—Pravastatin—atherosclerosis	0.000242	0.00174	CcSEcCtD
Alprostadil—Dizziness—Niacin—atherosclerosis	0.000238	0.00171	CcSEcCtD
Alprostadil—Dizziness—Pravastatin—atherosclerosis	0.000234	0.00169	CcSEcCtD
Alprostadil—Nausea—Simvastatin—atherosclerosis	0.000233	0.00167	CcSEcCtD
Alprostadil—Rash—Niacin—atherosclerosis	0.000227	0.00163	CcSEcCtD
Alprostadil—Dermatitis—Niacin—atherosclerosis	0.000227	0.00163	CcSEcCtD
Alprostadil—Headache—Niacin—atherosclerosis	0.000225	0.00162	CcSEcCtD
Alprostadil—Rash—Pravastatin—atherosclerosis	0.000223	0.00161	CcSEcCtD
Alprostadil—Dermatitis—Pravastatin—atherosclerosis	0.000223	0.00161	CcSEcCtD
Alprostadil—Headache—Pravastatin—atherosclerosis	0.000222	0.0016	CcSEcCtD
Alprostadil—Nausea—Niacin—atherosclerosis	0.000214	0.00154	CcSEcCtD
Alprostadil—Nausea—Pravastatin—atherosclerosis	0.00021	0.00151	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—PRKCG—atherosclerosis	4.78e-05	0.000389	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KNG1—atherosclerosis	4.77e-05	0.000388	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PLG—atherosclerosis	4.75e-05	0.000387	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGTR1—atherosclerosis	4.75e-05	0.000386	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCL2—atherosclerosis	4.66e-05	0.000379	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PLG—atherosclerosis	4.62e-05	0.000376	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CYBA—atherosclerosis	4.61e-05	0.000375	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EDN1—atherosclerosis	4.6e-05	0.000374	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EDN1—atherosclerosis	4.6e-05	0.000374	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL5—atherosclerosis	4.56e-05	0.000371	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL5—atherosclerosis	4.56e-05	0.000371	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PARP1—atherosclerosis	4.51e-05	0.000367	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PRKCG—atherosclerosis	4.51e-05	0.000367	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NAMPT—atherosclerosis	4.47e-05	0.000364	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LIPC—atherosclerosis	4.44e-05	0.000362	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOC3—atherosclerosis	4.42e-05	0.000359	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CD36—atherosclerosis	4.4e-05	0.000358	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LDLR—atherosclerosis	4.39e-05	0.000357	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—HMOX1—atherosclerosis	4.39e-05	0.000357	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SOCS3—atherosclerosis	4.38e-05	0.000356	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PRKCG—atherosclerosis	4.34e-05	0.000353	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PRKCG—atherosclerosis	4.34e-05	0.000353	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VWF—atherosclerosis	4.32e-05	0.000352	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VWF—atherosclerosis	4.32e-05	0.000352	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOC3—atherosclerosis	4.29e-05	0.000349	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOC3—atherosclerosis	4.29e-05	0.000349	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CETP—atherosclerosis	4.29e-05	0.000349	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LDLR—atherosclerosis	4.27e-05	0.000347	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LDLR—atherosclerosis	4.27e-05	0.000347	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP3—atherosclerosis	4.23e-05	0.000344	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF2—atherosclerosis	4.21e-05	0.000343	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGT—atherosclerosis	4.2e-05	0.000342	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGT—atherosclerosis	4.2e-05	0.000342	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—APOB—atherosclerosis	4.2e-05	0.000342	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL3—atherosclerosis	4.17e-05	0.000339	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL3—atherosclerosis	4.17e-05	0.000339	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SCARB1—atherosclerosis	4.11e-05	0.000334	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOB—atherosclerosis	4.09e-05	0.000333	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—atherosclerosis	4.07e-05	0.000331	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PDGFB—atherosclerosis	4.06e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—atherosclerosis	4.05e-05	0.00033	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EDN1—atherosclerosis	4.02e-05	0.000327	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MMP1—atherosclerosis	4.02e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NCF1—atherosclerosis	3.99e-05	0.000325	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NCF1—atherosclerosis	3.99e-05	0.000325	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL5—atherosclerosis	3.99e-05	0.000325	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ALB—atherosclerosis	3.98e-05	0.000324	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LPL—atherosclerosis	3.9e-05	0.000318	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—F2—atherosclerosis	3.89e-05	0.000316	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—F2—atherosclerosis	3.89e-05	0.000316	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMGCR—atherosclerosis	3.88e-05	0.000315	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CAV1—atherosclerosis	3.85e-05	0.000313	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	3.85e-05	0.000313	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—APOA1—atherosclerosis	3.84e-05	0.000313	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGT—atherosclerosis	3.82e-05	0.000311	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGT—atherosclerosis	3.82e-05	0.000311	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—atherosclerosis	3.8e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PRKCG—atherosclerosis	3.8e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDNRA—atherosclerosis	3.77e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDNRA—atherosclerosis	3.77e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCR2—atherosclerosis	3.77e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCR2—atherosclerosis	3.77e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CYBA—atherosclerosis	3.75e-05	0.000305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CYBA—atherosclerosis	3.75e-05	0.000305	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	3.73e-05	0.000304	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CG—atherosclerosis	3.72e-05	0.000303	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CG—atherosclerosis	3.72e-05	0.000303	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SPP1—atherosclerosis	3.7e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—atherosclerosis	3.68e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GHRL—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GHRL—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PARP1—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLAT—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PARP1—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLAT—atherosclerosis	3.67e-05	0.000299	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—F2—atherosclerosis	3.66e-05	0.000298	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS2—atherosclerosis	3.62e-05	0.000295	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PPARA—atherosclerosis	3.54e-05	0.000288	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—F2—atherosclerosis	3.53e-05	0.000287	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—F2—atherosclerosis	3.53e-05	0.000287	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—atherosclerosis	3.52e-05	0.000286	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CG—atherosclerosis	3.51e-05	0.000285	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ABCA1—atherosclerosis	3.46e-05	0.000281	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PDGFB—atherosclerosis	3.42e-05	0.000278	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOB—atherosclerosis	3.39e-05	0.000276	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CG—atherosclerosis	3.38e-05	0.000275	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CG—atherosclerosis	3.38e-05	0.000275	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGT—atherosclerosis	3.34e-05	0.000272	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—MAPK3—atherosclerosis	3.33e-05	0.000271	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—APOA1—atherosclerosis	3.32e-05	0.000271	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOE—atherosclerosis	3.27e-05	0.000266	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LEP—atherosclerosis	3.27e-05	0.000266	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CAV1—atherosclerosis	3.24e-05	0.000264	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LPL—atherosclerosis	3.24e-05	0.000263	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOA1—atherosclerosis	3.23e-05	0.000263	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—atherosclerosis	3.23e-05	0.000263	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KNG1—atherosclerosis	3.22e-05	0.000262	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KNG1—atherosclerosis	3.22e-05	0.000262	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—atherosclerosis	3.21e-05	0.000261	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR1—atherosclerosis	3.21e-05	0.000261	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR1—atherosclerosis	3.21e-05	0.000261	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PRKCG—atherosclerosis	3.15e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL2—atherosclerosis	3.14e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL2—atherosclerosis	3.14e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—atherosclerosis	3.12e-05	0.000254	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLG—atherosclerosis	3.12e-05	0.000254	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLG—atherosclerosis	3.12e-05	0.000254	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—F2—atherosclerosis	3.09e-05	0.000251	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—atherosclerosis	3.05e-05	0.000248	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—atherosclerosis	3.04e-05	0.000248	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—atherosclerosis	2.96e-05	0.000241	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SOCS3—atherosclerosis	2.96e-05	0.000241	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SOCS3—atherosclerosis	2.96e-05	0.000241	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—atherosclerosis	2.95e-05	0.00024	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—atherosclerosis	2.92e-05	0.000237	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS3—atherosclerosis	2.91e-05	0.000237	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP3—atherosclerosis	2.86e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP3—atherosclerosis	2.86e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF2—atherosclerosis	2.84e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF2—atherosclerosis	2.84e-05	0.000231	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOB—atherosclerosis	2.84e-05	0.000231	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PDGFB—atherosclerosis	2.84e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK3—atherosclerosis	2.83e-05	0.00023	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—INS—atherosclerosis	2.8e-05	0.000227	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—atherosclerosis	2.76e-05	0.000225	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOB—atherosclerosis	2.76e-05	0.000225	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOB—atherosclerosis	2.76e-05	0.000225	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL2—atherosclerosis	2.75e-05	0.000224	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—atherosclerosis	2.74e-05	0.000223	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—atherosclerosis	2.74e-05	0.000223	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDN1—atherosclerosis	2.72e-05	0.000221	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDN1—atherosclerosis	2.72e-05	0.000221	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOE—atherosclerosis	2.71e-05	0.000221	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LPL—atherosclerosis	2.71e-05	0.000221	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—atherosclerosis	2.7e-05	0.00022	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL5—atherosclerosis	2.7e-05	0.000219	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL5—atherosclerosis	2.7e-05	0.000219	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CAV1—atherosclerosis	2.69e-05	0.000219	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOA1—atherosclerosis	2.68e-05	0.000218	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—atherosclerosis	2.65e-05	0.000215	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LPL—atherosclerosis	2.64e-05	0.000215	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LPL—atherosclerosis	2.64e-05	0.000215	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—atherosclerosis	2.63e-05	0.000214	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	2.6e-05	0.000211	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CD36—atherosclerosis	2.58e-05	0.00021	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—atherosclerosis	2.57e-05	0.000209	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCG—atherosclerosis	2.56e-05	0.000209	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCG—atherosclerosis	2.56e-05	0.000209	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—atherosclerosis	2.53e-05	0.000206	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SPP1—atherosclerosis	2.5e-05	0.000203	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SPP1—atherosclerosis	2.5e-05	0.000203	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—atherosclerosis	2.49e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—atherosclerosis	2.49e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOS3—atherosclerosis	2.45e-05	0.000199	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—atherosclerosis	2.44e-05	0.000199	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARA—atherosclerosis	2.4e-05	0.000195	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGT—atherosclerosis	2.32e-05	0.000189	CbGpPWpGaD
Alprostadil—ABCC5—Disease—INS—atherosclerosis	2.32e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDGFB—atherosclerosis	2.31e-05	0.000188	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDGFB—atherosclerosis	2.31e-05	0.000188	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOE—atherosclerosis	2.27e-05	0.000185	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGT—atherosclerosis	2.26e-05	0.000184	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGT—atherosclerosis	2.26e-05	0.000184	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CAV1—atherosclerosis	2.25e-05	0.000183	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOA1—atherosclerosis	2.25e-05	0.000183	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—atherosclerosis	2.24e-05	0.000183	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOE—atherosclerosis	2.21e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOE—atherosclerosis	2.21e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LEP—atherosclerosis	2.21e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LEP—atherosclerosis	2.21e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CAV1—atherosclerosis	2.19e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CAV1—atherosclerosis	2.19e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOA1—atherosclerosis	2.18e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOA1—atherosclerosis	2.18e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—atherosclerosis	2.17e-05	0.000177	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—atherosclerosis	2.13e-05	0.000173	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—atherosclerosis	2.11e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—atherosclerosis	2.11e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—atherosclerosis	2.1e-05	0.000171	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—atherosclerosis	2.1e-05	0.000171	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—F2—atherosclerosis	2.08e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—F2—atherosclerosis	2.08e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—atherosclerosis	2.07e-05	0.000168	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—atherosclerosis	2.05e-05	0.000167	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS3—atherosclerosis	2.03e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—atherosclerosis	1.99e-05	0.000162	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—atherosclerosis	1.99e-05	0.000162	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK3—atherosclerosis	1.98e-05	0.000161	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—atherosclerosis	1.98e-05	0.000161	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—atherosclerosis	1.97e-05	0.00016	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NFKB1—atherosclerosis	1.95e-05	0.000158	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—INS—atherosclerosis	1.94e-05	0.000158	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—atherosclerosis	1.92e-05	0.000157	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK8—atherosclerosis	1.91e-05	0.000156	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK3—atherosclerosis	1.91e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK3—atherosclerosis	1.91e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—atherosclerosis	1.91e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—INS—atherosclerosis	1.89e-05	0.000154	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—INS—atherosclerosis	1.89e-05	0.000154	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—atherosclerosis	1.86e-05	0.000151	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL2—atherosclerosis	1.86e-05	0.000151	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL2—atherosclerosis	1.86e-05	0.000151	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—atherosclerosis	1.83e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—atherosclerosis	1.83e-05	0.000149	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—atherosclerosis	1.78e-05	0.000145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—atherosclerosis	1.77e-05	0.000144	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—atherosclerosis	1.75e-05	0.000142	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—atherosclerosis	1.73e-05	0.000141	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—atherosclerosis	1.73e-05	0.000141	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NOS3—atherosclerosis	1.7e-05	0.000139	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK3—atherosclerosis	1.67e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOS3—atherosclerosis	1.66e-05	0.000135	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOS3—atherosclerosis	1.66e-05	0.000135	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—atherosclerosis	1.62e-05	0.000132	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—atherosclerosis	1.56e-05	0.000127	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—atherosclerosis	1.47e-05	0.00012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—atherosclerosis	1.47e-05	0.00012	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—atherosclerosis	1.45e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—atherosclerosis	1.42e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—atherosclerosis	1.42e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—atherosclerosis	1.4e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—atherosclerosis	1.4e-05	0.000114	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK3—atherosclerosis	1.39e-05	0.000113	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—atherosclerosis	1.34e-05	0.000109	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—atherosclerosis	1.34e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—atherosclerosis	1.33e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—atherosclerosis	1.33e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFKB1—atherosclerosis	1.31e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFKB1—atherosclerosis	1.31e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK8—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK8—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—atherosclerosis	1.22e-05	9.94e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—atherosclerosis	1.19e-05	9.71e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—atherosclerosis	1.19e-05	9.71e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—atherosclerosis	1.18e-05	9.61e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—atherosclerosis	1.18e-05	9.61e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK3—atherosclerosis	1.13e-05	9.18e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK3—atherosclerosis	1.13e-05	9.18e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—atherosclerosis	1.13e-05	9.17e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—atherosclerosis	1.09e-05	8.91e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—atherosclerosis	1.09e-05	8.91e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—atherosclerosis	1.01e-05	8.24e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—atherosclerosis	9.35e-06	7.6e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—atherosclerosis	8.25e-06	6.71e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—atherosclerosis	8.25e-06	6.71e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—atherosclerosis	7.83e-06	6.37e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—atherosclerosis	7.61e-06	6.19e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—atherosclerosis	7.61e-06	6.19e-05	CbGpPWpGaD
